GH therapy in noonan syndrome: Review of final height data

Hormone Research

Volumn 72, Issue SUPPL. 2, 2009, Pages 46-48

  Dahlgren, Jovanna ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Adult height; GH treatment; Mutation; PTPN11

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE SHP 2; RECOMBINANT GROWTH HORMONE;

BODY HEIGHT; CONFERENCE PAPER; GENE MUTATION; GENOTYPE; GROWTH ACCELERATION; GROWTH CURVE; HORMONAL THERAPY; HUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; BODY HEIGHT; CHILD; FEMALE; GENOTYPE; GROWTH; HUMAN GROWTH HORMONE; HUMANS; MALE; MUTATION; NOONAN SYNDROME; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PUBERTY; SEX FACTORS;

EID: 73849105803     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000243779     Document Type: Conference Paper

References (16)

1. Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA: The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child 1974; 127: 48-55.
2. Witt DR, Keena BA, Hall JG, Allanson AJ: Growth curves for height in Noonan syndrome. Clin Genet 1986; 30: 150-153.
3. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR: Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 1988; 148: 220-227.
4. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA: The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 2007; 92: 128-132.
5. Kelnar CJ: Growth hormone therapy in Noonan syndrome. Horm Res 2000; 53 (suppl 1):77-81.
6. Binder G, Neuer K, Ranke MB, Wittekindt NE: PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005; 90: 5377-5381.
7. Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA: PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 2005; 90: 5156-5160.
8. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y: Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 2006; 91: 300-306.
9. Osio D, Dahlgren J, Wikland KA, Westphal O: Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr 2005; 94: 1232-1237.
10. Raaijmakers R, Noordam C, Karagiannis G, Gregory JW, Hertel NT, et al: Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database. J Pediatr Endocrinol Metab 2008; 21: 267-273.
11. Noordam C, Peer PGM, Francois I, De Schepper J, van den Burgt I, Otten BJ: Longterm GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 2008; 159: 203-208.
12. Kirk JMW, Betts PR, Butler GE, Donaldson MDC, Dunger DB, Johnston DI, Kelnar CJH, DA Price, Wilton P: Short stature in Noonan syndrome: response to growth hormone therapy. Arch Dis Child 2001; 84: 440-443.
13. Romano AA, Blethen SL, Dana K, Noto RA: Growth hormone treatment in Noonan syndrome: The National Cooperative Growth Study experience. J Pediatr 1996; 128:S18-S21.
14. Municchi G, Pasquino AM, Pucarelli I, Cianfarani S, Passeri F: Growth hormone treatment in Noonan syndrome: report of four cases who reached final height. Horm Res 1995; 44: 164-167.
15. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD: Mutations in PTPN11 , encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465-468.
16. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS: Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39: 70-74.